These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 19692477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [Abstract] [Full Text] [Related]

  • 3. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR.
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Selection and immune recognition of HIV-1 MPER mimotopes.
    Wieczorek L, Peachman K, Steers N, Schoen J, Rao M, Polonis V, Rao V.
    Virology; 2020 Nov; 550():99-108. PubMed ID: 32980676
    [Abstract] [Full Text] [Related]

  • 11. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M, Yuan F, Liu Y, Jiang S, Song X, Jiang P, Yin X, Ding M, Deng H.
    Vaccine; 2006 Jan 23; 24(4):435-42. PubMed ID: 16143433
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.
    J Virol; 2008 Dec 23; 82(23):11651-68. PubMed ID: 18815292
    [Abstract] [Full Text] [Related]

  • 14. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
    Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC.
    J Virol; 2009 Aug 23; 83(15):7397-410. PubMed ID: 19458010
    [Abstract] [Full Text] [Related]

  • 15. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J, Wyatt RT.
    PLoS Pathog; 2012 Aug 23; 8(7):e1002806. PubMed ID: 22829767
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.